{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:12:01Z","timestamp":1784754721159,"version":"3.55.0"},"reference-count":15,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T00:00:00Z","timestamp":1402531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Diabetes Sci Technol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Galactomannan is an insoluble polysaccharide that has been shown to reduce postprandial excursions. We assessed the impact of a novel galactomannan derivative (PAZ320) on the magnitude of 2-hour postprandial glucose excursions in individuals with type 2 diabetes who were being treated with oral medication and\/or insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Investigators recently reported findings from a single-center, open-label, prospective study that evaluated the efficacy of PAZ320 in 24 subjects with type 2 diabetes who were treated with oral antidiabetic agents and\/or insulin. End points included adverse events and area under the curve during 3-hour postprandial glucose excursion (gAUC). Subjects consumed a test meal without PAZ320 at baseline and then ingested low-dose (8 g) and high-dose (16 g) PAZ320 with test meals at subsequent intervention visits. A post hoc analysis was conducted to determine changes in 2-hour postprandial glucose excursions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 20 subjects for whom data were available for all clinic visit test meals, 15 (75%) responded to low-dose, high-dose, or both medication dosages. Low-dose responders (n = 8) experienced clinically significant improvements in 2-hour postprandial glucose excursions from baseline excursions compared with nonresponders (\u201328.00 \u00b1 25.97 mg\/dL vs 23.42 \u00b1 11.45 mg\/dL, P = .005). Similar differences were seen in high-dose responders (\u201328.82 \u00b1 24.26 vs 33.89 \u00b1 20.56 mg\/dL, P &lt; .0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PAZ320 was shown to be safe in all patients studied and effective in controlling postprandial glucose in a large portion of the study population. Additional studies are needed to determine its long-term effects on HbA1c and to further define which subpopulation(s) may respond to PAZ320 therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1932296814538939","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T03:49:47Z","timestamp":1402631387000},"page":"1018-1022","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and\/or Insulin"],"prefix":"10.1177","volume":"8","author":[{"given":"Laura E.","family":"Trask","sequence":"first","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Department of Medicine, Section of Endocrinology, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushela S.","family":"Chaidarun","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Department of Medicine, Section of Endocrinology, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Platt","sequence":"additional","affiliation":[{"name":"Boston Therapeutics, Inc, Manchester, NH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Parkin","sequence":"additional","affiliation":[{"name":"CGParkin Communications, Inc, Boulder City, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"key":"bibr1-1932296814538939","first-page":"E572","volume":"270","author":"Byrne MM","year":"1996","journal-title":"Am J Physiol"},{"key":"bibr2-1932296814538939","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-6-1447"},{"key":"bibr3-1932296814538939","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.5.506"},{"key":"bibr4-1932296814538939","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2007.S117"},{"key":"bibr5-1932296814538939","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.08.158"},{"key":"bibr6-1932296814538939","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.11.2626"},{"key":"bibr7-1932296814538939","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00059-3"},{"key":"bibr8-1932296814538939","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1005"},{"key":"bibr9-1932296814538939","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.12.1830"},{"key":"bibr10-1932296814538939","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000034509.14906.AE"},{"key":"bibr11-1932296814538939","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2000"},{"key":"bibr12-1932296814538939","doi-asserted-by":"publisher","DOI":"10.4158\/EP12327.OR"},{"key":"bibr13-1932296814538939","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540350075038"},{"key":"bibr14-1932296814538939","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.7.815"},{"key":"bibr15-1932296814538939","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1732"}],"container-title":["Journal of Diabetes Science and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1932296814538939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1932296814538939","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1932296814538939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:11:06Z","timestamp":1777399866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1932296814538939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1177\/1932296814538939"],"URL":"https:\/\/doi.org\/10.1177\/1932296814538939","relation":{},"ISSN":["1932-2968","1932-2968"],"issn-type":[{"value":"1932-2968","type":"print"},{"value":"1932-2968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,12]]}}}